VALENSCION

pharmaceuticals for use in the treatment of viral infection, bacterial infection, asthma, allergies, cancer, transplant rejection, inflammatory diseases and disorders, immune diseases and disorders, hereditary diseases and disorders, and auto immune diseases and disorders; pharmaceuticals for use in the treatment of influenza, AIDS, SARS, Ebola, Zika, and West Nile virus; pharmaceuticals for use in the treatment of hereditary angioedema; pharmaceuticals for use in the treatment of T-cell and B-cell leukemias and lymphomas; medical therapeutic preparations, namely, biologically active modulators, biologically active immune modulators, biologically active antisense DNA or RNA compounds, chemical modulators of gene expression working at DNA transcription, RNA or translation processes; immunomodulatory oligonucleotides, namely, ingredients that enhance or induce an immune response as a component part in a pharmaceutical preparation; pharmaceutical and vaccine adjuvants to enhance the immune system response; medical therapeutic preparations, namely, small molecule chemicals aimed at inhibiting cellular proteins